読み込み中
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.
前日終値
$1.08
−$0.03 · -2.70%
日中の時刻はETです。市場データは遅延する場合があります。
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.
日中レンジ
現在 $1.08
52週レンジ
現在 $1.08
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
72
割安
センチメント
53
まちまち
リスク
66
高リスク
モメンタム
47
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.
日中レンジ
現在 $1.08
52週レンジ
現在 $1.08
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（AUD） | 2026年度 | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|---|
| 売上高 | 754.5万 AUD | 728.7万 AUD | 490.29万 AUD | 180.47万 AUD | 76.52万 AUD |
| 売上原価 | 267.87万 AUD | 252.19万 AUD | 156.61万 AUD | 6.46万 AUD | 24.17万 AUD |
| 粗利益 | 486.64万 AUD | 476.51万 AUD | 333.68万 AUD | 174.01万 AUD | 52.35万 AUD |
| 研究開発 | — | 359.73万 AUD | 537.55万 AUD | 259.21万 AUD | 65.77万 AUD |
| 販売・一般管理 | 760.72万 AUD | 793.6万 AUD | 658.54万 AUD | 514.83万 AUD | 394.09万 AUD |
| 営業費用 | 949.84万 AUD | 1010.96万 AUD | 913.79万 AUD | 530.89万 AUD | 339.34万 AUD |
| 受取利息 | — | 13.59万 AUD | 32.78万 AUD | 11.63万 AUD | 2.18万 AUD |
| 支払利息 | 1.44万 AUD | 7305 AUD | 7576 AUD | 9652 AUD | 6184 AUD |
| 減価償却費と償却費 | — | 4.97万 AUD | 4.42万 AUD | 4.87万 AUD | 2.66万 AUD |
| 営業利益 | −463.2万 AUD | −534.45万 AUD | −580.11万 AUD | −356.88万 AUD | −286.99万 AUD |
| 純利益 | −375.48万 AUD | −521.6万 AUD | −693.7万 AUD | −378.65万 AUD | −285.43万 AUD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
